scholarly journals Efficacy and Safety of Lycoprozen®, a Novel Tomato-Based Food Supplement in Patients with Benign Prostatic Hyperplasia

2018 ◽  
Vol 3 (2) ◽  
pp. 1-5
Author(s):  
Alberto Cellini ◽  
Pier Giorgio Natali ◽  
Manuela Iezzi ◽  
Mauro Piantelli ◽  
Vincenzo Fogliano ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Side Effects ◽  
Food Supplement ◽  
Prostatic Hyperplasia ◽  
Controlled Study ◽  
P Value ◽  
Efficacy And Safety ◽  
Suitable Alternative ◽  
International Prostatic Symptom Score ◽  
Before And After

Objective: To evaluate the efficacy and safety of a novel tomato-based food supplement on the lower urinary tract symptoms (LUTS) of patients with benign prostatic hyperplasia (BPH). Methods: Twenty patients with BPH were enrolled in this observational study. They were assigned to consume daily a sachet of Lycoprozen® (5 grams) dissolved in water for two months. Results: All patients successfully completed the Lycoprozen scheduled regimen and the IPSS (International Prostatic Symptom Score) questionnaire before and after treatment. No side effects due to treatment were noticed. In this preliminary study, we have found that Lycoprozen® significantly reduced the LUTS severity (paired t-test, two-tailed p value < 0.0001). The IPSS mean values before and after the treatment were 16.95+6.0 SD (range 31-6) and 12.2+4.9 SD (range 20-2), respectively. Conclusions: Based on these data, Lycoprozen® may represent a suitable alternative option for the treatment of symptomatic BPH patients which worth of further testing in a phase 2 prospective randomized double blind placebo controlled study. The treatment was without side effects and acceptance among patients was high.

scholarly journals Improvement of Urinary Tract Symptoms and Quality of Life in Benign Prostate Hyperplasia Patients, Associated with Consumption of a Newly Developed whole Tomato Based Food Supplement. A phase II prospective, Randomized Double-blinded, Placebo-controlled Study.

2020 ◽  
Author(s):  
Luigi Cormio ◽  
Beppe Calò ◽  
Manuela Iezzi ◽  
Alessia Lamolinara ◽  
Paola Vitaglione ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Phase Ii ◽  
Food Supplement ◽  
Prostatic Hyperplasia ◽  
Controlled Study ◽  
Before And After ◽  
Double Blinded

Abstract Background: Benign prostatic hyperplasia is the most common urologic disease among elderly men. The diagnosis of BPH is usually in response to the appearance of lower urinary tract obstructive, and post-micturition symptoms (LUTS) that can significantly affect the quality of life. In Aim of this study was to evaluate in a phase II prospective, randomized double-blinded, placebo-controlled study, the efficacy and safety of a novel whole tomato-based food supplement on LUTS of patients affected by benign prostatic hyperplasia. Methods: Thirty-four consecutive patients with histologically proved BPH were included in a phase II prospective, randomized double-blinded, placebo-controlled study. Patients were randomized to receive daily for two months a sachet (5 grams) of the tomato-based food supplement Lycoprozen® or an identical sachet containing placebo. Patients were asked to fill the “International Prostatic Symptom Score” questionnaire before and after treatment. Results: All patients successfully completed the scheduled regimen. No side effects were recorded. Lycoprozen® significantly reduced the LUTS severity. Particularly, the IPSS mean values before and after the treatment were 7.5+1.1 SE (range 16-2) and 5.1+1.0 SD (range 14-2), respectively (paired t-test, two-tailed p value <0.0002). A trend toward a reduction of total PSA levels was observed in Lycoprozen® treated patients (9.346 ng/ml+1.839 SE vs.7.906+0.928 SE, P = 0.096) (Fig 1, left). This trend was sustained by the significant reduction of PSA levels seen in 5 patients, (2 obese, 2 over-weight and 1 normal-weight) with basal levels >10 ng/ml (18.520ng/ml+2.747 SE vs. 10.323ng/ml+2.073 SE, P = 0.009)

scholarly journals Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
René Arnouk ◽  
Carlos Henrique Suzuki Bellucci ◽  
Roberto Benatuil Stull ◽  
José de Bessa Junior ◽  
Cesar Augusto Malave ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Botulinum Neurotoxin ◽  
Prostate Volume ◽  
Randomized Study ◽  
Maximum Flow ◽  
Type A ◽  
Prostatic Hyperplasia ◽  
Efficacy And Safety ◽  
International Prostatic Symptom Score ◽  
Botulinum Neurotoxin Type A

Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH).Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups.Results. Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Qmaxand PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups.Conclusions. Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.

scholarly journals Improvement of sexual function in men with benign prostatic hyperplasia by pharmacologic therapy

2014 ◽  
Vol 142 (9-10) ◽  
pp. 572-578 ◽  
Author(s):  
Nebojsa Stojanovic ◽  
Dragan Bogdanovic
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Side Effects ◽  
Sexual Function ◽  
Combined Therapy ◽  
Prostatic Hyperplasia ◽  
Pharmacologic Therapy ◽  
Alpha Blockers ◽  
Alpha Blocker ◽  
Reductase Inhibitors ◽  
Before And After

Introduction. Benign prostatic hyperplasia (BPH) causes disorders of voiding and sexual function. Pharmacologic therapy reduces symptoms of voiding thus impacting sexual function. Objective. To determine sex life status in men with BPH before and after pharmacologic treatment adapted to achieve satisfactory sexual function. Methods. We studied 117 sexually active BPH patients, not previously treated for BPH. After clinical examinations, symptoms of voiding, sexual and ejaculatory function were measured using standardized IPSS, IIEF and MSHQ-EjD questionnaires. After obtaining patients? personal opinion about the importance of their sex life, therapy was chosen and possible side effects explained. Three groups of 39 patients each were formed. The first group was treated with alpha-blocker, tamsulosin, the second with 5-alpha reductase inhibitor, finasteride, while the third group was administered a combination therapy. The complete examination procedure was repeated after 3 and 6 months of therapy. Results. The average age of patients was 61.34?3.04 years. Eighty-seven percent reported that their sex life was important to a certain degree. Satisfaction with their sex life was reported by 47% of patients before treatment and by 67% of respondents 6 months after treatment. Questionnaire scores indicated general improvement of sexual function in all groups, which was statistically significant compared to baseline only in the group on tamsulosin alpha-blocker (2.95?7.81; p=0.028). The overall satisfaction with sex life as a component of sexual function, improved significantly in the group on the combined therapy (0.78?1.81; p=0.012). Conclusion. Before BPH treatment sexual function should be assessed and therapy customized to the patient?s expectations. Side effects of drugs should be presented especially to patients who emphasize the importance of sex life. In the manifested stages of the disease overall satisfaction with sex life may be improved by combined therapy comprising 5-alpha reductase inhibitors and third generation alpha blockers. In earlier stages, BPH alpha blockers monotherapy may improve overall sexual function.

Sign in / Sign up

Export Citation Format

Share Document